Stable flow cytometric markers for malignant myeloid cells are highly warranted. Based on data from stem cell research, we hypothesized that the human inhibitory C-type lectin like receptor (hMICL) might represent a novel diagnostic and prognostic vehicle in a standard flow cytometry (FCM) setting.
Larsen, H. Ø., Roug, A. S., Just, T., Brown, G. D., & Hokland, P. (2012). Expression of the hMICL in acute myeloid leukemia: a highly reliable disease marker at diagnosis and during follow-up. Cytometry Part B: Clinical Cytometry, 82B(1), 3-8. https://doi.org/10.1002/cyto.b.20614